Navigation Links
EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
Date:3/21/2013

ROCKVILLE, Md., March 21, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2012. 

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

The Company reported a net loss of ($0.4 million), or ($0.02) per share for the three months ended December 31, 2012.  This compares with net income of $1.0 million, or $0.06 per share for the fourth quarter 2011.  The increase in net loss is directly attributed to the decrease in revenues from royalties earned from Celgene Corporation's sales of Thalomid® in the fourth quarter of fiscal 2012 compared to fiscal 2011.

For the year ended December 31, 2012 the net loss, excluding non-cash interest expense, was ($4.5 million), or ($0.25) per share as compared to ($4.6 million), or ($0.47) per share for 2011. The reported net loss for the year ended December 31, 2012 included non-cash interest charges totaling $10.0 million associated with the Company's 2012 financing, recorded in accordance with US generally accepted accounting principles. Including the non-cash interest expense, the reported net loss for the year ended December 31, 2012 was ($14.5 million), or ($0.78) per share.

As of December 31, 2012, EntreMed had cash and cash equivalents of approximately $8.0 million.  The cash position has since been strengthened by approximately $10.3 million in net proceeds from a financing which was completed on March 14, 2013. 

Sara B. Capitelli , Vice President, Finance and Principal Accounting Officer, commented, "Our financial results for the fourth quarter are in line with our e
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Reports First Quarter 2012 Financial Results
2. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
3. EntreMed Reports Second Quarter 2012 Financial Results
4. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
5. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
6. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
7. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
10. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
11. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/11/2014)... SAN DIEGO , July 11, 2014 ... Therapies Corp. ("Biotie") to end the option held by ... to commence further development of NRL-1 (intranasal diazepam) for ... seizures. Over the past year, Biotie has ... Neurelis in preparation for the pivotal clinical work required ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... treatment initiation and longer exposure to Betaseron ... sclerosis, MONTREAL, Sept. 19 Data ... Research in Multiple Sclerosis (WCTRIMS) demonstrated that,early ... a,greater impact on long-term outcomes, when compared ...
... 19 Novavax, Inc.,(Nasdaq: NVAX ) a clinical-stage ... Chief Executive Officer, will be presenting at,the 2008 UBS ... is being held September 22-25, 2008 at The Grand ... 2008 at 10:30 am.,Eastern Time. Dr. Singhvi will provide ...
Cached Medicine Technology:New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R) 2New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R) 3New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R) 4New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R) 5
(Date:7/11/2014)... 2014 The Europe Well Intervention Market report ... with analysis and revenue forecast. The well intervention services market ... in 2013 to $3.4 billion by 2018, at a CAGR ... TOC of the Europe Well Intervention Market report, to get ... a glimpse of the segmentation in the Europe well intervention ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... CT (PRWEB) July 11, 2014 ... the nation’s only non-profit dedicated exclusively to cell ... that Joshua Corday has joined the organization as ... fundraising professional with deep experience securing gifts and ... served as Annual Giving Director for NewYork Presbyterian ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... 6 percent of U.S. hospital emergency departments are fully ... of novel H1N1 (swine) flu expected this winter, the ... In a joint policy statement published in Pediatrics ... Department," pediatric emergency medicine specialists and others provide recommendations ...
... Federal stimulus funding is helping a Kansas State University ... Their research is creating a clearer picture of a ... chronic diseases like cancer. Katsura Asano, K-State associate ... from the National Institutes of Health,s National Institute of ...
... so-called junk DNA to be cut and pasted within genetic ... therapies. The study by researchers at the University of ... in which shifted genes have a significant effect on the ... antibody genes can enable the immune system to target infection ...
... NEW YORK, Sept. 21 Within the first three seconds ... in many first encounters, from the first day of school to the ... help you exude confidence, so follow these helpful tips to get yourself ... go to: http://www.prnewswire.com/mnr/crest/39172/ , , ...
... INDIANAPOLIS, Sept. 21 Eli Lilly and Company ... on the Human Rights Campaign,s (HRC) Corporate Equality Index for 2010. ... the Best Places to Work for Lesbian, Gay, Bisexual, and Transgender (LGBT) ... organization,s efforts related to creating an equitable environment for lesbian, gay, bisexual, ...
... , , ABBOTT PARK, Ill., Sept. 21 ... from the U.S. Food and Drug Administration (FDA) for its ABBOTT PRISM ... HIV-1/HIV-2. This test can be used by laboratory professionals to screen ... type 1 Groups M and O (anti-HIV-1) and type 2 (anti-HIV-2), and ...
Cached Medicine News:Health News:Photos: Fall's First Impressions 2Health News:Lilly Receives 100 Percent Rating on Corporate Equality Index Survey 2Health News:Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2 2Health News:Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2 3
... to use instruments for nerve location: our ... stimulator, and muscle locator, together with a ... pencil point needles., ,The RDG Nerve ... to use stimulator, designed to facilitate the ...
... Based on the original MS-III ... electrosurgery certification, enhanced keypad ... ,The MiniStim® MS-IV peripheral ... for neuromuscular monitoring in operating ...
... beyond your investment., ,The Centiva/5 Critical Care ... time demands of the critical care environment. The ... mind combining a compact size with high levels ... valuable space around the patients bed and allows ...
... is combining a lightweight mesh material with the ... hernia plug which stands for a high patient ... material is included in Premilene Mesh LP Self-Forming ... for a softer and less bulky Plug Premilene ...
Medicine Products: